Literature DB >> 20297864

Adverse drug reactions in the paediatric population in Denmark: a retrospective analysis of reports made to the Danish Medicines Agency from 1998 to 2007.

Lise Aagaard1, Camilla Blicher Weber, Ebba Holme Hansen.   

Abstract

BACKGROUND: The potential risk of adverse drug reactions (ADRs) in the paediatric population has become a public health concern and regulatory agencies in Europe and the US have acknowledged that there is a need for more research in this area. Spontaneous reporting systems can provide important new information about ADRs.
OBJECTIVE: To characterize ADRs in children reported in Denmark over a period of one decade.
METHODS: We analysed ADRs reported to the Danish Medicines Agency from 1998 to 2007 for individuals aged from birth to 17 years. Data were analysed with respect to time, age and sex, category of ADR (System Organ Class [SOC]), seriousness, suspected medicines (level 2 of the Anatomical Therapeutic Chemical [ATC] Classification System) and type of reporter.
RESULTS: 2437 ADR reports corresponding to 4500 ADRs were analysed. On average, 234 ADR reports were submitted annually, corresponding to approximately two ADRs per report. From 2003 to 2005, an increasing number of ADRs submitted per report were observed, but after 2005 the reporting rate decreased. One-half of ADRs were reported for infants from birth to 2 years of age. Similar total numbers of ADRs were reported for boys and girls. The majority of ADRs reported were from the following SOCs: general disorders and administration site conditions (31%), skin and subcutaneous tissue disorders (18%) and nervous system disorders (15%). Reports encompassed medicines from ATC group J: vaccines and anti-infectives for systemic use (65%); and ATC group N: nervous system (17%). On average, 42% of ADRs were classified as serious. ATC group N had the highest proportion of ADRs that were classified as serious. Although physicians reported approximately 90% of the ADRs, a relatively large proportion of serious ADRs were reported by other sources.
CONCLUSION: In Denmark, the ADR reporting rate in the paediatric population has declined since 2005. The majority of ADRs reported in young children were reported for vaccines and anti-infectives, but also a high number of serious ADRs were reported for medicines from ATC group N. The Danish Medicines Agency should monitor prescribing patterns more tightly to identify potential risks in the paediatric population in relation to the evolving pattern of medicine use among children.

Entities:  

Mesh:

Year:  2010        PMID: 20297864     DOI: 10.2165/11319100-000000000-00000

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  22 in total

1.  Adverse drug reactions in children reported by means of the yellow card in Spain.

Authors:  F J Morales-Olivas; I Martínez-Mir; J M Ferrer; E Rubio; V Palop
Journal:  J Clin Epidemiol       Date:  2000-10       Impact factor: 6.437

2.  Reported adverse drug reactions and their determinants in Dutch children outside the hospital.

Authors:  Eric Schirm; Hilde Tobi; Eugène P van Puijenbroek; Margje H Monster-Simons; Lolkje T W de Jong-van den Berg
Journal:  Pharmacoepidemiol Drug Saf       Date:  2004-03       Impact factor: 2.890

3.  Clinical trials of medication in children, 1996-2002.

Authors:  H M Sammons; I Choonara
Journal:  Eur J Clin Pharmacol       Date:  2005-03-11       Impact factor: 2.953

4.  Prioritizing children's medicines for research: a pharmaco-epidemiological study of antiepileptic drugs.

Authors:  Ruth Ackers; Macey L Murray; Frank M C Besag; Ian C K Wong
Journal:  Br J Clin Pharmacol       Date:  2007-01-25       Impact factor: 4.335

5.  Creating knowledge about adverse drug reactions: a critical analysis of the Danish reporting system from 1968 to 2005.

Authors:  Lise Aagaard; Birthe Soendergaard; Elin Andersen; Jens Peter Kampmann; Ebba Holme Hansen
Journal:  Soc Sci Med       Date:  2007-06-12       Impact factor: 4.634

Review 6.  Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies.

Authors:  P Impicciatore; I Choonara; A Clarkson; D Provasi; C Pandolfini; M Bonati
Journal:  Br J Clin Pharmacol       Date:  2001-07       Impact factor: 4.335

7.  Paediatric adverse drug reaction reporting: understanding and future directions.

Authors:  Bruce C Carleton; M Anne Smith; Michaela N Gelin; Susan C Heathcote
Journal:  Can J Clin Pharmacol       Date:  2007-02-12

8.  Opening the white boxes: the licensing documentation of efficacy and safety of psychotropic medicines for children.

Authors:  Lise Aagaard; Steffen Thirstrup; Ebba Holme Hansen
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-05       Impact factor: 2.890

9.  Adverse drug reaction reporting by patients in the Netherlands: three years of experience.

Authors:  Joyce de Langen; Florence van Hunsel; Anneke Passier; Lolkje de Jong-van den Berg; Kees van Grootheest
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

10.  Drug use in children: cohort study in three European countries.

Authors:  Miriam C J M Sturkenboom; Katia M C Verhamme; Alfredo Nicolosi; Macey L Murray; Antje Neubert; Daan Caudri; Gino Picelli; Elif Fatma Sen; Carlo Giaquinto; Luigi Cantarutti; Paola Baiardi; Maria-Grazia Felisi; Adriana Ceci; Ian C K Wong
Journal:  BMJ       Date:  2008-11-24
View more
  30 in total

1.  Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase.

Authors:  Kristina Star; G Niklas Norén; Karin Nordin; I Ralph Edwards
Journal:  Drug Saf       Date:  2011-05-01       Impact factor: 5.606

2.  Vaccine-based subgroup analysis in VigiBase: effect on sensitivity in paediatric signal detection.

Authors:  Sandra de Bie; Katia M C Verhamme; Sabine M J M Straus; Bruno H Ch Stricker; Miriam C J M Sturkenboom
Journal:  Drug Saf       Date:  2012-04-01       Impact factor: 5.606

3.  Adverse drug reactions reported for systemic antibacterials in Danish children over a decade.

Authors:  Lise Aagaard; Ebba Holme Hansen
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

4.  Rates of spontaneous reports of adverse drug reactions for drugs reported in children: a cross-sectional study with data from the Swedish adverse drug reaction database and the Swedish Prescribed Drug Register.

Authors:  Susanna M Wallerstedt; Gertrud Brunlöf; Anders Sundström
Journal:  Drug Saf       Date:  2011-08-01       Impact factor: 5.606

Review 5.  Adverse drug reactions associated with asthma medications in children: systematic review of clinical trials.

Authors:  Lise Aagaard; Ebba Holme Hansen
Journal:  Int J Clin Pharm       Date:  2014-02-23

6.  Neonatal adverse drug reactions: an analysis of reports to the French pharmacovigilance database.

Authors:  Florentia Kaguelidou; Frédérique Beau-Salinas; Annie Pierre Jonville-Bera; Evelyne Jacqz-Aigrain
Journal:  Br J Clin Pharmacol       Date:  2016-07-24       Impact factor: 4.335

7.  Parental reporting of adverse drug events and other drug-related problems in children in Finland.

Authors:  L Lindell-Osuagwu; K Sepponen; S Farooqui; H Kokki; K Hämeen-Anttila; K Vainio
Journal:  Eur J Clin Pharmacol       Date:  2012-10-24       Impact factor: 2.953

8.  Adverse drug reactions in children reported by European consumers from 2007 to 2011.

Authors:  Lise Aagaard; Ebba Holme Hansen
Journal:  Int J Clin Pharm       Date:  2013-11-05

9.  Drug-induced anaphylaxis: a decade review of reporting to the Portuguese Pharmacovigilance Authority.

Authors:  Inês Ribeiro-Vaz; Joana Marques; Pascal Demoly; Jorge Polónia; Eva Rebelo Gomes
Journal:  Eur J Clin Pharmacol       Date:  2012-08-23       Impact factor: 2.953

10.  Adverse drug reactions in hospitalized pediatric patients of Saudi Arabian University Hospital and impact of pharmacovigilance in reporting ADR.

Authors:  Lateef M Khan; Sameer E Al-Harthi; Omar I Saadah
Journal:  Saudi Pharm J       Date:  2012-10-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.